Panacea Index Logo

Command Palette

Search for a command to run...

Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147).

Molecular biology reports
October 1, 2020
Ahmet Ozer Sehirli et al. (3 authors)
Journal ArticleReviewHuman Study
Study Details

Study Goal

The researchers aimed to evaluate the potential protective effect of melatonin in COVID-19, mediated by its suppression of CD147 protein activity.

Results Summary

The study suggests melatonin may prevent severe symptoms and reduce symptom severity in COVID-19 by blocking CD147 activity, which mediates viral invasion and cytokine storms. It also highlights melatonin's potential to mitigate adverse effects of other antiviral drugs.

Population

COVID-19 patients, particularly the elderly and immune-compromised.

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (4)
InterventionDirectionEndpointPopulationDosageImpactClaim #
melatonin
decrease
cardiac damage
-
-
reduce cardiac damage
#1
melatonin
decrease
severe symptoms
COVID-19 patients
-
prevent severe symptoms
#2
melatonin
decrease
symptom severity
COVID-19 patients
-
reduce symptom severity
#3
melatonin
decrease
adverse effects of the other antiviral drugs
COVID-19 patients
-
reduce the adverse effects
#4
Abstract

COVID-19 caused by the SARS-CoV-2 outbreak quickly has turned into a pandemic. However, no specific antiviral agent is yet available. In this communication, we aimed to evaluate the significance of CD147 protein and the potential protective effect of melatonin that is mediated by this protein in COVID-19. CD147 is a glycoprotein that is responsible for the cytokine storm in the lungs through the mediation of viral invasion. Melatonin use previously was shown to reduce cardiac damage by blocking the CD147 activity. Hence, melatonin, a safe drug, may prevent severe symptoms, reduce symptom severity and the adverse effects of the other antiviral drugs in COVID-19 patients. In conclusion, the use of melatonin, which is reduced in the elderly and immune-compromised patients, should be considered as an adjuvant through its CD147 suppressor and immunomodulatory effect.

Medical Subject Headings (MeSH)
Adjuvants, PharmaceuticAnimalsAntioxidantsAntiviral AgentsBasiginCOVID-19Coronavirus InfectionsHumansImmune SystemMelatoninPandemicsPneumonia, ViralSignal Transduction
Study Links
Quality Scores
Safety85
Efficacy70/10
Quality60/10
Citation Metrics
Total Citations38
Citations/Year7.6
Relative Citation Ratio2.12
NIH Percentile76.3%
Research Impact Scores
APT Score0.75
Weight Score1.08
Normalized Score0.74
Related Supplements